Financial Ratios Neuronetics, Inc.
Equities
STIM
US64131A1051
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.460 USD | +7.89% | +5.13% | +52.80% |
Jan. 13 | Neuronetics, Inc. Announces Unaudited Revenue Results for Fourth Quarter and Full Year 2024 | CI |
Jan. 13 | Neuronetics, Inc. Provides Earnings Guidance for the Full Year 2025 | CI |
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
Return on Assets | -15.5 | -14.34 | -15.39 | -16.71 | -15.34 | |||
Return on Total Capital | -18.33 | -17.56 | -17.94 | -19.47 | -18.45 | |||
Return On Equity % | -48.86 | -74.86 | -56.37 | -52.25 | -66.17 | |||
Return on Common Equity | -48.86 | -74.86 | -56.37 | -52.25 | -66.17 | |||
Margin Analysis | ||||||||
Gross Profit Margin % | 75.44 | 76.54 | 78.93 | 76.26 | 75.13 | |||
SG&A Margin | 96.48 | 99.5 | 113.54 | 114.86 | 101.82 | |||
EBITDA Margin % | -41.28 | -39.74 | -47.01 | -50.4 | -37.34 | |||
EBITA Margin % | -42.98 | -41.65 | -48.93 | -52.93 | -40.02 | |||
EBIT Margin % | -42.98 | -41.65 | -48.93 | -52.93 | -40.02 | |||
Income From Continuing Operations Margin % | -46.35 | -55.75 | -56.39 | -56.99 | -42.31 | |||
Net Income Margin % | -46.35 | -55.75 | -56.39 | -56.99 | -42.31 | |||
Net Avail. For Common Margin % | -46.35 | -55.75 | -56.39 | -56.99 | -42.31 | |||
Normalized Net Income Margin | -28.97 | -31.39 | -34.68 | -35.04 | -27.23 | |||
Levered Free Cash Flow Margin | -25.5 | -34.8 | -29 | -30.86 | -28.38 | |||
Unlevered Free Cash Flow Margin | -21.82 | -29.06 | -24.46 | -26.79 | -23.63 | |||
Asset Turnover | ||||||||
Asset Turnover | 0.58 | 0.55 | 0.5 | 0.51 | 0.61 | |||
Fixed Assets Turnover | 19.95 | 10.88 | 11.96 | 12.51 | 14.13 | |||
Receivables Turnover (Average Receivables) | 9.59 | 5.97 | 5.84 | 5.21 | 4.49 | |||
Inventory Turnover (Average Inventory) | 5.91 | 3.56 | 2.27 | 2 | 2.09 | |||
Short Term Liquidity | ||||||||
Current Ratio | 3.19 | 4.75 | 7.34 | 2.98 | 4.73 | |||
Quick Ratio | 3 | 4.24 | 6.63 | 2.57 | 4 | |||
Operating Cash Flow to Current Liabilities | -1.1 | -2.07 | -1.78 | -0.93 | -1.62 | |||
Days Sales Outstanding (Average Receivables) | 38.07 | 61.32 | 62.55 | 70.06 | 81.38 | |||
Days Outstanding Inventory (Average Inventory) | 61.75 | 102.87 | 161.04 | 182.25 | 174.78 | |||
Average Days Payable Outstanding | 97.22 | 122.6 | 101.32 | 68.95 | 77.42 | |||
Cash Conversion Cycle (Average Days) | 2.59 | 41.59 | 122.27 | 183.37 | 178.74 | |||
Long Term Solvency | ||||||||
Total Debt/Equity | 71.73 | 150.37 | 46.43 | 69.65 | 182.73 | |||
Total Debt / Total Capital | 41.77 | 60.06 | 31.71 | 41.06 | 64.63 | |||
LT Debt/Equity | 47.06 | 148.04 | 45.64 | 45.21 | 180.25 | |||
Long-Term Debt / Total Capital | 27.4 | 59.13 | 31.17 | 26.65 | 63.76 | |||
Total Liabilities / Total Assets | 52.23 | 67.59 | 39.69 | 51.18 | 70.48 | |||
EBIT / Interest Expense | -7.31 | -4.54 | -6.73 | -8.12 | -5.26 | |||
EBITDA / Interest Expense | -6.88 | -4.19 | -6.3 | -7.54 | -4.76 | |||
(EBITDA - Capex) / Interest Expense | -7.1 | -4.36 | -6.88 | -8.31 | -5.2 | |||
Total Debt / EBITDA | -1.35 | -2.02 | -1.56 | -1.24 | -2.42 | |||
Net Debt / EBITDA | 1.63 | 0.56 | 2.16 | 0.95 | -0.11 | |||
Total Debt / (EBITDA - Capex) | -1.31 | -1.95 | -1.43 | -1.12 | -2.21 | |||
Net Debt / (EBITDA - Capex) | 1.58 | 0.54 | 1.97 | 0.87 | -0.1 | |||
Growth Over Prior Year | ||||||||
Total Revenues, 1 Yr. Growth % | 18.72 | -21.41 | 12.32 | 17.89 | 9.42 | |||
Gross Profit, 1 Yr. Growth % | 17.2 | -20.26 | 15.84 | 13.89 | 7.81 | |||
EBITDA, 1 Yr. Growth % | 36.48 | -24.35 | 32.89 | 26.38 | -20.63 | |||
EBITA, 1 Yr. Growth % | 35.78 | -23.84 | 31.96 | 27.52 | -18.68 | |||
EBIT, 1 Yr. Growth % | 35.78 | -23.84 | 31.96 | 27.52 | -18.68 | |||
Earnings From Cont. Operations, 1 Yr. Growth % | 20.53 | -5.48 | 13.62 | 19.13 | -18.76 | |||
Net Income, 1 Yr. Growth % | 20.53 | -5.48 | 13.62 | 19.13 | -18.76 | |||
Normalized Net Income, 1 Yr. Growth % | 21.03 | -14.86 | 24.12 | 19.11 | -16.34 | |||
Diluted EPS Before Extra, 1 Yr. Growth % | -41.32 | -7.76 | -16.01 | 12.83 | -23.74 | |||
Accounts Receivable, 1 Yr. Growth % | 32.54 | 21.53 | 9.4 | 52.76 | 10.3 | |||
Inventory, 1 Yr. Growth % | 14.1 | 34.05 | 76.42 | 35.59 | -9.06 | |||
Net Property, Plant and Equip., 1 Yr. Growth % | 255.81 | -15.4 | 23.05 | 4.19 | -10.08 | |||
Total Assets, 1 Yr. Growth % | -14.4 | -21.48 | 79.54 | -17.23 | -0.9 | |||
Tangible Book Value, 1 Yr. Growth % | -33.39 | -47.93 | 250.62 | -35.34 | -43.9 | |||
Common Equity, 1 Yr. Growth % | -32.64 | -46.73 | 234.11 | -33.01 | -40.08 | |||
Cash From Operations, 1 Yr. Growth % | 48.04 | -6.86 | -1.43 | 9.85 | 4.23 | |||
Capital Expenditures, 1 Yr. Growth % | -19.58 | -10.21 | 222.33 | 38.93 | -27.53 | |||
Levered Free Cash Flow, 1 Yr. Growth % | 17.87 | 7.27 | -6.4 | 25.45 | -1.21 | |||
Unlevered Free Cash Flow, 1 Yr. Growth % | 21.55 | 4.67 | -5.47 | 29.1 | -5.5 | |||
Compound Annual Growth Rate Over Two Years | ||||||||
Total Revenues, 2 Yr. CAGR % | 24.48 | -3.4 | -6.04 | 15.07 | 13.57 | |||
Gross Profit, 2 Yr. CAGR % | 23.88 | -3.33 | -3.89 | 14.86 | 10.81 | |||
EBITDA, 2 Yr. CAGR % | 40.99 | 1.61 | 0.27 | 24.01 | 0.16 | |||
EBITA, 2 Yr. CAGR % | 40.68 | 1.69 | 0.25 | 24.38 | 1.78 | |||
EBIT, 2 Yr. CAGR % | 40.68 | 1.69 | 0.25 | 24.38 | 1.78 | |||
Earnings From Cont. Operations, 2 Yr. CAGR % | 34.48 | 6.74 | 3.63 | 16.34 | -1.62 | |||
Net Income, 2 Yr. CAGR % | 34.48 | 6.74 | 3.63 | 16.34 | -1.62 | |||
Normalized Net Income, 2 Yr. CAGR % | 34.48 | 1.3 | 2.8 | 17.39 | -0.17 | |||
Diluted EPS Before Extra, 2 Yr. CAGR % | -86.47 | -26.43 | -11.98 | -2.65 | -7.24 | |||
Accounts Receivable, 2 Yr. CAGR % | 32.13 | 26.92 | 15.31 | 29.27 | 29.8 | |||
Inventory, 2 Yr. CAGR % | 6.04 | 23.68 | 53.79 | 54.67 | 11.05 | |||
Net Property, Plant and Equip., 2 Yr. CAGR % | 89.94 | 73.5 | 2.03 | 13.23 | -3.21 | |||
Total Assets, 2 Yr. CAGR % | 60.39 | -18.01 | 18.74 | 21.9 | -9.44 | |||
Tangible Book Value, 2 Yr. CAGR % | -50.84 | -41.11 | 35.12 | 48.35 | -39.77 | |||
Common Equity, 2 Yr. CAGR % | -50.16 | -40.1 | 33.42 | 49.61 | -36.64 | |||
Cash From Operations, 2 Yr. CAGR % | 65.39 | 17.42 | -4.19 | 4.05 | 7 | |||
Capital Expenditures, 2 Yr. CAGR % | 16.99 | -15.03 | 70.12 | 111.61 | 0.34 | |||
Levered Free Cash Flow, 2 Yr. CAGR % | 36.35 | 12.44 | 0.2 | 4.97 | 11.28 | |||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 41.41 | 12.79 | -0.53 | 6.37 | 10.37 | |||
Compound Annual Growth Rate Over Three Years | ||||||||
Total Revenues, 3 Yr. CAGR % | 22.33 | 6.79 | 1.58 | 1.34 | 13.16 | |||
Gross Profit, 3 Yr. CAGR % | 19.63 | 6.96 | 2.68 | 1.7 | 12.46 | |||
EBITDA, 3 Yr. CAGR % | 43.99 | 14.57 | 11.12 | 8.31 | 7.62 | |||
EBITA, 3 Yr. CAGR % | 42.35 | 14.65 | 10.92 | 8.62 | 8.57 | |||
EBIT, 3 Yr. CAGR % | 42.35 | 14.65 | 10.92 | 8.62 | 8.57 | |||
Earnings From Cont. Operations, 3 Yr. CAGR % |